Tyra Biosciences, Inc. (TYRA) — SEC Filings
Tyra Biosciences, Inc. (TYRA) — 42 SEC filings. Latest: ARS (Apr 17, 2026). Includes 15 8-K, 8 SC 13D/A, 6 SC 13G/A.
View Tyra Biosciences, Inc. on SEC EDGAR
Overview
Tyra Biosciences, Inc. (TYRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 17, 2026: On April 16, 2026, Tyra Biosciences, Inc. filed an 8-K report detailing the departure of Dr. Todd Manetta from his role as Chief Medical Officer. The filing also announced the appointment of Dr. Jessica Lee as the new Chief Medical Officer, effective immediately. Dr. Lee's compensation details were
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 40 neutral, 2 mixed. The dominant filing sentiment for Tyra Biosciences, Inc. is neutral.
Filing Type Overview
Tyra Biosciences, Inc. (TYRA) has filed 2 144, 1 ARS, 1 DEFA14A, 15 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 8 SC 13D/A, 6 SC 13G/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of TYRA's 30 recent filings, 0 were flagged as high-risk, 21 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Dr. Todd Manetta
- Dr. Jessica Lee
- Todd A. Brady
- Kaplan Gilla
- Dr. Todd M. W. Green
- Dr. Jeffrey W. Chen
- Dr. Todd M. W. Johnson
- Aaron I. Davis
- Josh La Grange
- Peter Kolchinsky
- Dr. Todd W. P. Bracher
- Ms. Sarah E. Kelly
- Dr. Jeffrey W. Tobias
- Abigail P. Johnson
- Joe Lewis
Industry Context
Tyra Biosciences, Inc. is a biotechnology company operating in the pharmaceutical preparations sector.
Top Tags
10-Q (5) · financials (5) · biotech (5) · amendment (5) · corporate-governance (4) · ownership-change (4) · personnel (3) · sec-filing (3) · Tyra Biosciences (3) · executive-appointment (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| CMO Base Salary | $475,000 | Annual base compensation for the new Chief Medical Officer, Todd A. Brady. |
| CMO Target Bonus | 40% | Annual bonus potential for the new Chief Medical Officer, based on his base salary. |
| SEC File Number | 001-40800 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 83-1476348 | Company's tax identification number. |
| Reporting Period End Date | 2025-06-30 | Indicates the end of the fiscal quarter for which financial information is reported. |
| Filing Date | 2025-08-14 | The date the 10-Q was officially submitted to the SEC. |
| Reporting Period End | 2025-03-31 | The company's financial status is reported as of this date. |
| Fiscal Year End | 2024-12-31 | Reporting period for the 10-K |
| SIC Code | 2834 | Indicates the company operates in Pharmaceutical Preparations |
| Event Date | 20241010 | Date of event requiring filing |
| Reporting Period | Q2 2024 | The second quarter of 2024, ending June 30, 2024. |
| Prior Period End Date | 2023-12-31 | Referenced in financial statements |
| Standard Industrial Classification | 2834 | Pharmaceutical Preparations |
| Annual Meeting Date | May 29, 2024 | 2024 Annual Meeting of Stockholders |
| Annual Meeting Time | 10:00 a.m. Pacific Time | 2024 Annual Meeting of Stockholders |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, albeit potentially adjusted, stake in Tyra Biosciences, Inc. over the next year.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Tyra Biosciences, Inc. (TYRA)?
Tyra Biosciences, Inc. has 42 recent SEC filings from Feb 2024 to Apr 2026, including 15 8-K, 8 SC 13D/A, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TYRA filings?
Across 42 filings, the sentiment breakdown is: 40 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Tyra Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Tyra Biosciences, Inc. (TYRA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Tyra Biosciences, Inc.?
Key financial highlights from Tyra Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TYRA?
The investment thesis for TYRA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Tyra Biosciences, Inc.?
Key executives identified across Tyra Biosciences, Inc.'s filings include Dr. Todd Manetta, Dr. Jessica Lee, Todd A. Brady, Kaplan Gilla, Dr. Todd M. W. Green and 10 others.
What are the main risk factors for Tyra Biosciences, Inc. stock?
Of TYRA's 30 assessed filings, 0 were flagged high-risk, 21 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Tyra Biosciences, Inc.?
Recent forward-looking statements from Tyra Biosciences, Inc. include guidance on {"claim":"FMR LLC will maintain a significant, albeit potentially adjusted, stake in Tyra Biosciences, Inc. over the nex.